Risperidone in the treatment of psychosis of Alzheimer disease: Results from a prospective clinical trial

American Journal of Geriatric Psychiatry

Volumn 14, Issue 3, 2006, Pages 280-291

  Mintzer, Jacobo ^a,b   Greenspan, Andrew ^a   Caers, Ivo ^a   Van Hove, Ilse ^a   Kushner, Stuart ^a   Weiner, Myron ^a   Gharabawi, Georges ^a   Schneider, Lon S ^a  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alzheimer disease; Psychosis; Risperidone

Indexed keywords

GLUCOSE; PLACEBO; PROLACTIN; RISPERIDONE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEMALE; HEMATOMA; HUMAN; INJURY; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MORTALITY; MULTICENTER STUDY; NURSING HOME; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; URINARY TRACT INFECTION;

EID: 33644885707     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JGP.0000194643.63245.8c     Document Type: Article

References (18)

1. Laughren T: A regulatory perspective on psychiatric syndromes in Alzheimer disease. Am J Geriatr Psychiatry 2001; 9:340-345
2. Jeste DV, Finkel SI: Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000; 8:29-34
3. Paulsen JS, Salmon DP, Thal LJ, et al: Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000; 54:1965-1971
4. Chui HC, Lyness SA, Sobel E, et al: Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994; 51:676-681
5. Stern Y, Albert M, Brandt J, et al: Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology 1994; 44:2300-2307
6. Aarsland D, Cummings JL, Yenner G, et al: Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry 1996; 153:243-247
7. Tran M, Bedard M, Molloy DW, et al: Associations between psychotic symptoms and dependence in activities of daily living among older adults with Alzheimer's disease. Int Psychogeriatr 2003; 15:171-179
8. Cohen CA, Gold D, Shulman K, et al: Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 1993; 33:714-720
9. Alexopoulos GS, Silver JM, Kahn DA, et al: The Expert Consensus Guideline Series: treatment of agitation in older persons with dementia, Postgrad Med 1998; 1:1-88
10. Brodaty H, Ames D, Snowdon J, et al: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64:134-143
11. De Deyn PP, Rabheru K, Rasmussen A, et al: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53:946-955
12. Katz IR, Jeste DV, Mintzer JE, et al: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60:107-115
13. Brodaty H, Katz I, De Deyn PP, et al: Risperidone is effective in treating psychotic symptoms in patients with psychosis of Alzheimer's disease. Poster presented at The International College of Geriatric Psychoneuropharmacology (ICGP) 2004 Annual Meeting; October 14-17, 2004; Basel, Switzerland
14. Grossman F, Okamoto A, Turkoz I, et al: Risperidone in the treatment of elderly patients with psychosis of Alzheimer's Disease and related dementias [Letter]. J Am Geriatr Soc 2004; 52:852-853
15. Schneider LS, Katz IR, Park S, et al: Psychosis of Alzheimer disease. Validity of the construct and response to risperidone. Am J Geriatr Psychiatry 2003; 22:414-425
16. Reisberg B, Auer SR, Monteiro IM: Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr 1996; 8(suppl 3):301-308
17. Dahlke F, Lohaus A, Gutzmann H: Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research. Psychopharmacol Bull 1992; 28:425-432
18. U.S. Food and Drug Administration. FDA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01350. html. Accessed April 11, 2005.